Clinical trial
Prevention of Asthma With Levocetirizine 18 Month Treatment in Infants (12 - 24…
NCT00152464 · UCB Pharma SA, Industry · Completed
Key facts
| NCT number | NCT00152464 |
|---|---|
| Title | Prevention of Asthma With Levocetirizine 18 Month Treatment in Infants (12 - 24 Months) Suffering From Eczema (Atopic Dermatitis) and Sensitized to Grass Pollen and/or House Dust Mite (HDM) |
| Official title | The Early Prevention of Asthma in Atopic Children (EPAAC™) Study. A Multi-country, Double Blind, Placebo (PLC) Controlled, Randomized, Parallel Group Trial: Evaluation of the Efficacy and Safety of Levocetirizine (LCTZ) (5 mg/ml Oral Drops -0.125 mg/kg b.w. b.i.d.) Administered for 18 Months in… |
| Lead sponsor | UCB Pharma SA, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Dermatitis, Atopic |
| Intervention type | Drug |
| Interventions | Placebo, Levocetirizine |
| Enrollment | 514 |
| Start date | Mar 20, 2002 |
| Primary completion | Mar 15, 2006 |
| Completion | Mar 15, 2006 |
| First posted | Sep 9, 2005 |
| Last update posted | Jan 22, 2019 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: